Back to top

Sandoz announces U.S. FDA accepted for review two ANDAs for tirzepatide

Sandoz (SDZNY) announces that the US Food and Drug Administration, FDA, has accepted for review two Abbreviated New Drug Applications, ANDAs, for g...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sandoz Group AG Sponsored ADR (SDZNY)